Establish of new detection method of gene mutations using cell-free DNA in supernatant fluids
Project/Area Number |
26460462
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Human pathology
|
Research Institution | Kurume University |
Principal Investigator |
|
Project Period (FY) |
2014-04-01 – 2017-03-31
|
Project Status |
Completed (Fiscal Year 2016)
|
Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Keywords | 分子病理学 / 遊離DNA / EGFR遺伝子変異 / 体腔液細胞診 / 病理学 / 分子病理学的検査 / 細胞診 / 上澄みDNA / 液状化細胞診 / 肺癌 |
Outline of Final Research Achievements |
We examined whether it was possible to detect EGFR mutations in cytology cell-free DNA (ccfDNA) from the supernatant fluids of bronchial and effusion cytology samples. Quantity and fragmentation of ccfDNA in the supernatant fluid and cell damage and CC3 expression in the sediment gradually increased in a time dependent manner in the cell lines. In the 74 clinical samples, the detection of EGFR mutations using ccfDNA showed a high sensitivity in samples with malignant cells. In contrast, EGFR mutations were not found in negative samples. The twenty-two patients of EGFR mutations were detected in 63.6% of ccfDNA from supernatant fluids. EGFR mutations were found in 81.3% (13/16) of malignant cell patients, whereas EGFR mutations were not found in the negative samples. Our results suggest that ccfDNA might help to compensate for the lack of adequate DNA in EGFR mutation analysis, and ccfDNA supernatant fluids can be used to detect EGFR mutation in the same way as cancer cell sediments.
|
Report
(4 results)
Research Products
(12 results)
-
[Journal Article] EGFR mutation status in cell-free DNA supernatant of bronchial washings and brushings.2015
Author(s)
Kawahara A, Fukumitsu C, Taira T, Abe H, Takase Y, Mutara K, Yamaguchi T, Azuma K, Ishii H, Takamori S, Akiba J, Hoshono T, Kage M.
-
Journal Title
Cancer Cytopathology
Volume: 123
Issue: 10
Pages: 620-628
DOI
Related Report
Peer Reviewed
-
[Journal Article] Fixation effect of SurePath preservative fluids using EGFR mutation-specific antibodies for immunocytochemistry.2014
Author(s)
Kawahara A, Taira T, Abe H, Watari K, Murakami Y, Fukumitsu C, Takase Y, Yamaguchi T, Akiba J, Azuma K, Ono M, Kage M
-
Journal Title
Cancer Cytopathology
Volume: 122
Issue: 2
Pages: 145-152
DOI
Related Report
Peer Reviewed
-
-
[Journal Article] Evaluation of immunohistochemistry using two different antibodies and procedures for primary lung adenocarcinoma harboring anaplastic lymphoma kinase rearrangement2014
Author(s)
Akiba J, Kawahara A, Abe H, Azuma K, Yamaguchi T, Taira T, Fukumitsu C, Takase Y, Yasumoto M, Umeno Y, Todoroki K, Kurita T, Yamaguchi R, Kage M, Yano H
-
Journal Title
Oncol Letters
Volume: 8
Issue: 5
Pages: 2155-2159
DOI
Related Report
Peer Reviewed
-
[Journal Article] FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor2014
Author(s)
Azuma K, Kawahara A, Sonoda K, Nakashima K, Tashiro K, Watari K, Izumi H, Kage M, Kuwano M, Ono M, Hoshino T
-
Journal Title
Oncotarget
Volume: 5
Pages: 5908-5919
Related Report
Peer Reviewed
-
-
-
-
-
-
-